A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression
Section snippets
Cell culture and general reagents
C127 (a kind gift from Gordon Hager) and locus derepression (LDR) 6103 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with l-glutamine and high glucose, 1 mM sodium pyruvate, 0.1 mM minimal essential medium (MEM) nonessential amino acids, 1% (v/v) penicillin–streptomycin, and 10% heat-inactivated fetal bovine serum (FBS). All lung cancer cells (provided by John D. Minna) were maintained in RPMI 1640 media supplemented with 10% FBS. Immortalized normal human bronchial
Results
The LDR assay detects the derepression of a GFP reporter that is stably integrated in the mouse mammary carcinoma line, C127. In the vector, GFP transcription is controlled by a cytomegalovirus (CMV) promoter, which normally is strong and constitutively active. However, this cell line (referred to as LDR cells) was selected for lack of constitutive expression of the GFP reporter [12], presumably due to epigenetic silencing of the integration locus and/or methylation of the CMV promoter. GFP
Discussion
In this study, we used a cell-based imaging assay to screen for small molecules that activate expression of a silenced locus. Using qHTS, we identified six chemically distinct series of compounds that derepress or induce the GFP–GER reporter. Follow-up experiments revealed that compounds within three series were true reproducible actives, one series was inconclusive, and two series were false positive fluorescent. Compounds from each of the three active series did not inhibit HDAC enzymatic
Acknowledgments
We gratefully acknowledge Sam Michael and Carleen Klumpp for automation assistance, Ruili Huang for informatics support, Paul Shinn and Adam Yasgar for compound management, Jennifer Wichterman and Jianjun Chang for experimental assistance, Gordon Hager and John D. Minna for provision of cells, and Craig Thomas and David Shames for helpful discussions. This research was supported by the NIH Roadmap for Medical Research (through resources awarded under an X01 mechanism), by the National Cancer
References (35)
- et al.
The epigenomics of cancer
Cell
(2007) Chromatin modifications and their function
Cell
(2007)- et al.
Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening
J. Biol. Chem.
(2001) - et al.
Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays
Chem. Biol.
(2003) - et al.
High-content fluorescence-based screening for epigenetic modulators
Methods Enzymol.
(2006) - et al.
Fluorescent protein-based cellular assays analyzed by laser-scanning microplate cytometry in 1536-well plate format
Methods Enzymol.
(2006) - et al.
An estrogen receptor chimera senses ligands by nuclear translocation
J. Steroid Biochem. Mol. Biol.
(2005) - et al.
Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model
Biochem. Pharmacol.
(2004) - et al.
a putative negative regulator of yeast sir2 and human SIRT1
J. Biol. Chem.
(2002) - et al.
Histone deacetylase inhibitors open new doors in cancer therapy
Biochem. Pharmacol.
(2004)